Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 284-510-0 | CAS number: 84929-26-0 Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, etc., obtained from Commiphora myrrha, Burseraceae.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Ames test: non mutagenic (OECD 471, GLP, K, rel. 1).
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 November to 12 December 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study conducted according to OECD Guideline 471 without any deviation
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- dated 21 July 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Version / remarks:
- dated 30 May 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: ENV/EPOC(97)4 OECD Guideline for the Testing of Chemicals, Proposal for Replacement of Guidelines 471 and 472 Bacterial Reverse Mutation Test
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EEC Directive 2000/32, L1362000, Annex 4D, dated May 19, 2000
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Version / remarks:
- August 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: The Japanese Ministry of Economy Trade and Industry (METI), Ministry of Health, Labour and Welfare (MHLW) and Ministry of the Environment (MOE) Guidelines of 31 March 2011
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- 14 September 2015
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Storage: room temperature, darkness
- Target gene:
- The histidine dependent strains are derived from Salmonella typhimurium strain LT2 through mutations in the histidine locus. Additionally due to the "deep rough" (rfa-minus) mutation they possess a faulty lipopolysaccharide envelope which enables substances to penetrate the cell wall more easily. A further mutation causes a reduction in the activity of an excision repair system. The latter alteration includes mutational processes in the nitrate reductase and biotin genes produced in a UV-sensitive area of the gene named "uvrB-minus". In the strains TA 98 and TA 100 the R-factor plasmid pKM 101 carries the ampicillin resistance marker.
Strain Escherichia coli WP2 and its derivatives carry the same defect in one of the genes for tryptophan biosynthesis. Tryptophan-independent (Trp+) mutants (revertants) can arise either by a base change at the site of the original alteration or by a base change elsewhere in the chromosome so that the original defect is suppressed. This second possibility can occur in several different ways so that the system seems capable of detecting all types of mutagen which substitute one base for another. Additionally, the uvrA derivative is deficient in the DNA repair process (excision repair damage). Such a repair-deficient strain may be more readily mutated by agents. - Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Cytokinesis block (if used):
- Not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver homogenate metabolizing system (10% liver S9 in standard co-factors)
- Test concentrations with justification for top dose:
- Pre-Experiment/Experiment I: 3; 10; 33; 100; 333; 1000; 2500; and 5000 μg/plate with and without S9-mix
Experiment II:
Strain TA 100: 0.3; 1; 3; 10; 33; 100; 333; and 1000 μg/plate with and without S9-mix
The remaining strains: 33; 100; 333; 1000; 2500; and 5000 μg/plate with and without S9-mix - Vehicle / solvent:
- On the day of the experiment, the test item MYRRH ESSENTIAL OIL SOMALIA was dissolved in DMSO (purity > 99 %). The solvent was chosen because of its solubility properties and its relative nontoxicity to the bacteria
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- methylmethanesulfonate
- other: 4-nitro-o-phenylene-diamine and 2-aminoanthracene
- Details on test system and experimental conditions:
- SOURCE OF TEST SYSTEM: The bacterial strains TA 1535, TA 1537, TA 98, TA 100, and WP2 uvrA were obtained from Trinova Biochem GmbH (35394 Gießen, Germany).
METHOD OF APPLICATION:
EXPERIMENT: Experiment I (Plate Incorporation)
The following materials were mixed in a test tube and poured onto the selective agar plates:
100 µL Test solution at each dose level (solvent or reference mutagen solution (positive control)),
500 µL S9 mix (for test with metabolic activation) or S9 mix substitution buffer (for test without metabolic activation),
100 µL Bacteria suspension (cf. test system, pre-culture of the strains),
2000 µL Overlay agar
Experiment II (Pre-Incubation)
In the pre-incubation assay 100 µL test solution (solvent or reference mutagen solution (positive control)), 500 µL S9 mix / S9 mix substitution buffer and 100 µL bacterial suspension were mixed in a test tube and incubated at 37°C for 60 minutes. After pre-incubation 2.0 mL overlay agar (45°C) was added to each tube.
The mixture was poured on minimal agar plates. After solidification the plates were incubated upside down for at least 48 hours at 37°C in the dark.
In parallel to each test a sterile control of the test item was performed and documented in the raw data. Therefore, 100 µL of the stock solution, 500 µl S9 mix / S9 mix substitution buffer were mixed with 2.0 mL overlay agar and poured on minimal agar plates.
CONTROLS:
- Vehicle/solvent control: DMSO
- Negative (untreated) controls were performed to assess the spontaneous revertant colony rate.
- Positive control items used demonstrated a direct and indirect acting mutagenic effect depending on the presence or absence of metabolic activation
NUMBER OF REPLICATIONS: Triplicate
OTHER: PRE-EXPERIMENT: To evaluate the toxicity of the test item a pre-experiment was performed with all strains used. Eight concentrations were tested for toxicity and mutation induction with each 3 plates - Rationale for test conditions:
- In the pre-experiment the concentration range of the test item was 3 – 5000 μg/plate. The pre-experiment is reported as experiment I. Since toxic effects were observed in experiment I a minimum of six concentrations was tested in experiment II.
The concentration range included two logarithmic decades. The following concentrations were tested in experiment II:
Strain TA 100: 0.3; 1; 3; 10; 33; 100; 333; and 1000 μg/plate
The remaining strains: 33; 100; 333; 1000; 2500; and 5000 μg/plate - Evaluation criteria:
- The Salmonella typhimurium and Escherichia coli reverse mutation assay is considered acceptable if it meets the following criteria:
regular background growth in the negative and solvent control
the spontaneous reversion rates in the negative and solvent control are in the range of our historical data
the positive control substances should produce an increase above the threshold of twice (strains TA 98, TA 100, and WP2 uvrA) or thrice (strains TA 1535 and TA 1537) the colony count of the corresponding solvent control
a minimum of five analysable dose levels should be present with at least three dose levels showing no signs of toxic effects, evident as a reduction in the number of revertants below the indication factor of 0.5.
if precipitation occurs a minimum of four concentrations showing no precipitation should be analysed - Statistics:
- No statistics needed
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 333 to 5000 µg/plate in Exp 1 without S9, 1000 to 5000 µg/plate in Exp 1 with S9, 33 to 1000 µg/plate in Exp 2 without S9, 1000 µg/plate in Exp 2 with S9,
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Precipitation: Precipitation of the test item in the overlay agar on the incubated agar plates was observed in experiment I at 5000 μg/plate without S9 mix and from 2500 to 5000 μg/plate with S9 mix and in experiment II at 5000 μg/plate with and without S9 mix, except of strain TA 100, where, based on a lower top dose, no precipitation was observed.
Reduction growth: The plates incubated with the test item showed normal background growth up to 5000 μg/plate in experiment I in all strains used with and without S9 mix, and in experiment II in all strains used, except of strain TA 98 without S9 mix in experiment II, in which reduced background growth was observed at 5000 μg/plate.
MUTAGENICITY
- The vehicle (DMSO) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
No substantial increase in revertant colony numbers of any of the five tester strains was observed following treatment with MYRRH ESSENTIAL OIL SOMALIA at any concentration level, neither in the presence nor absence of metabolic activation (S9 mix). There was also no tendency of higher mutation rates with increasing concentrations in the range below the generally acknowledged border of biological relevance.
- Refer Tables 7.6.1/1 and 7.6.1/2 for more details and attached background for individual results.
HISTORICAL CONTROL DATA (with ranges, means and standard deviation
- Positive historical control data: Refer Table 7.6.1/3
- Negative (solvent/vehicle) historical control data: Refer Table 7.6.1/3 - Conclusions:
- In conclusion, it can be stated that during the described mutagenicity test and under the experimental conditions reported, the test item did not induce gene mutations by base pair changes or frameshifts in the genome of the strains used.
- Executive summary:
This study was performed to investigate the potential of MYRRH ESSENTIAL OIL SOMALIA to induce gene mutations according to the plate incorporation test (experiment I) and the pre-incubation test (experiment II) using the Salmonella typhimurium strains TA 1535, TA 1537, TA 98, TA 100, and the Escherichia coli strain WP2 uvrA.
The assay was performed in two independent experiments both with and without liver microsomal activation (S9 mix). Each concentration, including the controls, was tested in triplicate. The test item was tested at the following concentrations:
Pre-Experiment/Experiment I: 3; 10; 33; 100; 333; 1000; 2500; and 5000 µg/plate
Experiment II:
Strain TA 100: 0.3; 1; 3; 10; 33; 100; 333; and 1000 µg/plate
The remaining strains: 33; 100; 333; 1000; 2500; and 5000 µg/plate
Precipitation of the test item in the overlay agar on the incubated agar plates was observed in experiment I at 5000 µg/plate without S9 mix and from 2500 to 5000 µg/plate with S9 mix and in experiment II at 5000 µg/plate with and without S9 mix, except of strain TA 100, in which, based on a lower top dose, no precipitation was observed. The undissolved particles had no influence on the data recording.
The plates incubated with the test item showed normal background growth up to 5000 µg/plate in experiment I in all strains used with and without S9 mix, and in experiment II in all strains used, except of strain TA 98 without S9 mix, in which reduced background growth was observed at 5000 µg/plate.
Toxic effects, evident as a reduction in the number of revertants (below the indication factor of 0.5), occurred in strain TA 100 with and without S9 mix in both experiments. In the remaining strains no toxic effects were observed , neither with nor without metabolic activation.
No substantial increase in revertant colony numbers of any of the five tester strains was observed following treatment with MYRRH ESSENTIAL OIL SOMALIA at any dose level, neither in the presence nor absence of metabolic activation (S9 mix). There was also no tendency of higher mutation rates with increasing concentrations in the range below the generally acknowledged border of biological relevance.
Appropriate reference mutagens were used as positive controls and showed a distinct increase of induced revertant colonies.
Conclusion
In conclusion, it can be stated that during the described mutagenicity test and under the experimental conditions reported, the test item did not induce gene mutations by base pair changes or frameshifts in the genome of the strains used.
Therefore, MYRRH ESSENTIAL OIL SOMALIA is considered to be non-mutagenic in this Salmonella typhimurium and Escherichia coli reverse mutation assay.
Reference
Table 7.6.1 /1 Summary of Experiment I
Study Name: 1868502 |
Study Code: Envigo 1868502 |
Experiment: 1868502 VV Plate |
Date Plated: 23.11.2017 |
Assay Conditions: |
Date Counted: 27.11.2017 |
Metabolic Activation |
Test Group |
Dose Level (per plate) |
Revertant Colony Counts (Mean ±SD) |
||||
|
|
|
|
|
|
|
|
|
|
|
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
|
|
|
|
|
|
|
|
Without Activation |
DMSO |
|
11 ± 2 |
9 ± 4 |
25 ± 5 |
204 ± 14 |
30 ± 7 |
Untreated |
|
16 ± 6 |
15 ± 4 |
25 ± 4 |
216 ± 7 |
31 ± 2 |
|
MYRRH |
3 µg |
9 ± 2 |
10 ± 5 |
19 ± 7 |
216 ± 3 |
30 ± 3 |
|
ESSENTIAL |
10 µg |
11 ± 2 |
14 ± 2 |
25 ± 2 |
190 ± 16 |
32 ± 6 |
|
OIL SOMALIA |
33 µg |
12 ± 2 |
11 ± 5 |
26 ± 1 |
157 ± 13 |
22 ± 6 |
|
|
100 µg |
13 ± 3 |
10 ± 5 |
21 ± 7 |
115 ± 9 |
27 ± 7 |
|
|
333 µg |
8 ± 1 |
8 ± 3 |
21 ± 5 |
50 ± 8 |
26 ± 4 |
|
|
1000 µg |
9 ± 2 |
5 ± 1 |
21 ± 7 |
33 ± 9 |
24 ± 2 |
|
|
2500 µg |
7 ± 2 |
6 ± 3 |
17 ± 3 |
30 ± 3 |
35 ± 7 |
|
|
5000 µg |
8 ± 2P M |
7 ± 2P M |
15 ± 4P |
16 ± 5P M |
28 ± 4P M |
|
NaN3 |
10 µg |
1063 ± 74 |
|
|
1578 ± 60 |
|
|
4-NOPD |
10 µg |
|
|
398 ± 15 |
|
|
|
4-NOPD |
50 µg |
|
154 ± 14 |
|
|
|
|
MMS |
2.0 µL |
|
|
|
|
816 ± 45 |
|
|
|
|
|
|
|
|
|
With Activation |
DMSO |
|
12 ± 6 |
15 ± 5 |
40 ± 4 |
173 ± 48 |
41 ± 3 |
Untreated |
|
16 ± 6 |
14 ± 6 |
39 ± 4 |
208 ± 11 |
45 ± 3 |
|
MYRRH |
3 µg |
14 ± 4 |
16 ± 1 |
36 ± 8 |
183 ± 6 |
45 ± 4 |
|
ESSENTIAL |
10 µg |
15 ± 5 |
21 ± 5 |
30 ± 6 |
182 ± 16 |
38 ± 10 |
|
OIL SOMALIA |
33 µg |
13 ± 3 |
19 ± 7 |
39 ± 6 |
194 ± 27 |
38 ± 3 |
|
|
100 µg |
11 ± 4 |
20 ± 3 |
31 ± 8 |
166 ± 19 |
32 ± 8 |
|
|
333 µg |
9 ± 3 |
16 ± 6 |
29 ± 1 |
108 ± 19 |
41 ± 5 |
|
|
1000 µg |
14 ± 5 |
18 ± 8 |
23 ± 6 |
57 ± 7 |
38 ± 9 |
|
|
2500 µg |
8 ± 1P |
15 ± 5P |
34 ± 8P |
34 ± 8P |
32 ± 6P |
|
|
5000 µg |
7 ± 2P M |
11 ± 2P M |
29 ± 3P |
23 ± 4P M |
26 ± 1P M |
|
2-AA |
2.5 µg |
409 ± 28 |
148 ± 22 |
3617 ± 376 |
3167 ± 424 |
|
|
2-AA |
10.0 µg |
|
|
|
|
376 ± 39 |
|
|
|
|
|
|
|
|
|
Table 7.6.1/2 Summary of Experiment II
Study Name: 1868502 |
Study Code: Envigo 1868502 |
Experiment: 1868502 HV2 Pre |
Date Plated: 06.12.2017 |
Assay Conditions: |
Date Counted: 12.12.2017 |
Metabolic Activation |
Test Group |
Dose Level (per plate) |
Revertant Colony Counts (Mean ±SD) |
||||
|
|
|
|
|
|
|
|
|
|
|
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
|
|
|
|
|
|
|
|
Without Activation |
DMSO |
|
10 ± 3 |
11 ± 5 |
25 ± 2 |
159 ± 9 |
32 ± 5 |
Untreated |
|
13 ± 4 |
13 ± 3 |
30 ± 3 |
188 ± 21 |
34 ± 4 |
|
MYRRH |
0.3 µg |
|
|
|
148 ± 19 |
|
|
ESSENTIAL |
1 µg |
|
|
|
168 ± 9 |
|
|
OIL SOMALIA |
3 µg |
|
|
|
156 ± 12 |
|
|
|
10 µg |
|
|
|
166 ± 31 |
|
|
|
33 µg |
10 ± 3 |
13 ± 4 |
25 ± 7 |
63 ± 17 |
33 ± 6 |
|
|
100 µg |
11 ± 4 |
11 ± 4 |
26 ± 8 |
43 ± 4 |
30 ± 8 |
|
|
333 µg |
9 ± 3 |
11 ± 5 |
17 ± 3 |
37 ± 6 |
32 ± 6 |
|
|
1000 µg |
8 ± 1 |
11 ± 4 |
26 ± 4 |
24 ± 6 |
34 ± 9 |
|
|
2500 µg |
11 ± 3 |
11 ± 4 |
21 ± 2 |
|
28 ± 8 |
|
|
5000 µg |
7 ± 2P |
14 ± 1P M |
15 ± 2P M R |
|
40 ± 3P |
|
NaN3 |
10 µg |
1286 ± 152 |
|
|
2049 ± 117 |
|
|
4-NOPD |
10 µg |
|
|
430 ± 24 |
|
|
|
4-NOPD |
50 µg |
|
199 ± 18 |
|
|
|
|
MMS |
2.0 µL |
|
|
|
|
923 ± 27 |
|
|
|
|
|
|
|
|
|
With Activation |
DMSO |
|
15 ± 2 |
17 ± 1 |
42 ± 2 |
133 ± 17 |
44 ± 3 |
Untreated |
|
13 ± 5 |
21 ± 6 |
39 ± 4 |
196 ± 20 |
52 ± 1 |
|
MYRRH |
0.3 µg |
|
|
|
116 ± 21 |
|
|
ESSENTIAL |
1 µg |
|
|
|
152 ± 11 |
|
|
OIL SOMALIA |
3 µg |
|
|
|
159 ± 22 |
|
|
|
10 µg |
|
|
|
130 ± 13 |
|
|
|
33 µg |
14 ± 7 |
19 ± 8 |
43 ± 9 |
118 ± 16 |
43 ± 9 |
|
|
100 µg |
12 ± 4 |
16 ± 4 |
41 ± 9 |
119 ± 9 |
46 ± 7 |
|
|
333 µg |
14 ± 2 |
18 ± 8 |
35 ± 3 |
68 ± 5 |
52 ± 6 |
|
|
1000 µg |
13 ± 3 |
22 ± 6 |
40 ± 7 |
40 ± 10 |
43 ± 14 |
|
|
2500 µg |
14 ± 1 |
18 ± 2 |
31 ± 10 |
|
37 ± 6 |
|
|
5000 µg |
8 ± 2P M |
22 ± 5P M |
26 ± 2P M |
|
35 ± 6P |
|
2-AA |
2.5 µg |
521 ± 46 |
100 ± 11 |
4545 ± 252 |
2274 ± 323 |
|
|
2-AA |
10.0 µg |
|
|
|
|
589 ± 65 |
Key to Positive Controls |
Key to Plate Postfix Codes |
||
|
|
||
NaN3 2-AA 4-NOPD MMS |
sodium azide 2-aminoanthracene 4-nitro-o-phenylene-diamine methyl methane sulfonate |
P M R |
Precipitate Manual count Reduction growth |
Table 7.6.1/3/ Historical data
Strain |
|
without S9 mix |
with S9 mix |
||||||
|
|
Mean |
SD |
Min |
Max |
Mean |
SD |
Min |
Max |
|
Solvent control |
12 |
2.5 |
6 |
25 |
12 |
2.5 |
7 |
26 |
TA 1535 |
Untreated control |
12 |
3.1 |
6 |
28 |
12 |
2.9 |
7 |
26 |
|
Positive control |
1130 |
143.1 |
334 |
1816 |
388 |
58.2 |
176 |
668 |
|
Solvent control |
10 |
2.2 |
6 |
19 |
13 |
3.5 |
7 |
30 |
TA1537 |
Untreated control |
11 |
2.7 |
5 |
21 |
14 |
4.0 |
7 |
31 |
|
Positive control |
82 |
12.7 |
43 |
157 |
191 |
60.8 |
83 |
434 |
|
Solvent control |
25 |
4.4 |
13 |
43 |
34 |
6.2 |
15 |
58 |
TA 98 |
Untreated control |
27 |
4.9 |
12 |
43 |
37 |
6.5 |
11 |
57 |
|
Positive control |
378 |
73.7 |
211 |
627 |
3949 |
771.8 |
360 |
6586 |
|
Solvent control |
156 |
26.0 |
78 |
209 |
148 |
32.3 |
73 |
208 |
TA 100 |
Untreated control |
176 |
23.6 |
79 |
217 |
172 |
25.4 |
85 |
218 |
|
Positive control |
1966 |
293.2 |
498 |
2767 |
3798 |
830.4 |
536 |
6076 |
|
Solvent control |
41 |
5.6 |
27 |
63 |
50 |
6.8 |
28 |
72 |
WP2uvrA |
Untreated control |
42 |
5.8 |
30 |
63 |
52 |
6.8 |
36 |
88 |
|
Positive control |
798 |
362.7 |
319 |
4732 |
378 |
112.6 |
167 |
1265 |
Mean = mean value of revertants/plate
SD = standard deviation
Min = minimal value/Max = maximal value
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Table 7.6/1: Summary of genotoxicity test
Test n° |
Test / Guideline Reliability |
Focus |
Strains tested |
Metabolic activation |
Test concentration |
Statement |
1
Schultz, 2018 |
Ames Test (OECD 471) K, rel. 1 |
Gene mutation |
TA 1535, TA 1537, TA 98, TA 100, WP2 uvrA |
-S9 +S9 |
Up to cytotoxic or highest recommended concentration |
-S9 : non mutagenic +S9 : non mutagenic |
Justification for classification or non-classification
Harmonized classification:
The registered substance has no harmonized classification according to the Regulation (EC) No. 1272/2008.
Self-classification:
Based on the available information, no classification is proposed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.